Men's Hormone Health

Does testosterone replacement increase cardiovascular risk?

Large randomized data (including TRAVERSE) do not show a significant increase in major adverse cardiovascular events with testosterone therapy in hypogonadal men over median follow-up of roughly three years. Older observational studies conflict, and absolute risk depends on baseline cardiovascular disease, formulation, and monitoring.

Open deep analysis →

Does testosterone therapy suppress fertility in men?

Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal axis and reliably reduces spermatogenesis. Recovery after discontinuation is variable and may be incomplete in some men.

Open deep analysis →

Does testosterone therapy increase hematocrit and polycythemia risk?

Testosterone therapy commonly raises hematocrit; polycythemia is a recognized adverse effect requiring dose adjustment, formulation changes, or phlebotomy when thresholds are exceeded.

Open deep analysis →

Does estradiol level affect symptoms and bone health in men on testosterone therapy?

Estradiol in men derives largely from aromatization of testosterone and contributes to bone density and possibly symptom control. Over-suppression with aromatase inhibitors may impair bone health; optimal targets in clinical practice remain debated.

Open deep analysis →

Does testosterone therapy suppress fertility in men?

Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal axis and reliably reduces spermatogenesis. Recovery after discontinuation is variable and may be incomplete in some men.

Open deep analysis →

Does testosterone therapy increase hematocrit and polycythemia risk?

Testosterone therapy commonly raises hematocrit; polycythemia is a recognized adverse effect requiring dose adjustment, formulation changes, or phlebotomy when thresholds are exceeded.

Open deep analysis →

Does testosterone therapy reduce cardiovascular events?

TRAVERSE found no significant difference in major adverse cardiovascular events between testosterone and placebo over trial follow-up. Meta-analyses of earlier trials are mixed; testosterone should not be prescribed primarily for cardiovascular protection.

Open deep analysis →

Does testosterone replacement increase cardiovascular risk?

Large randomized data (including TRAVERSE) do not show a significant increase in major adverse cardiovascular events with testosterone therapy in hypogonadal men over median follow-up of roughly three years. Older observational studies conflict, and absolute risk depends on baseline cardiovascular disease, formulation, and monitoring.

Open deep analysis →

How should low testosterone be diagnosed in symptomatic men?

Diagnosis requires consistent symptoms plus repeatedly low morning total testosterone on valid assays, with secondary causes excluded. A single borderline value should prompt repeat testing before initiating therapy.

Open deep analysis →

Does testosterone therapy increase prostate cancer risk?

Current systematic reviews and trial secondary analyses do not show a convincing increase in prostate cancer incidence among hypogonadal men treated with testosterone, though surveillance remains standard practice.

Open deep analysis →

Does testosterone therapy increase venous thromboembolism risk?

Large observational cohorts suggest a modest increase in venous thromboembolism risk with testosterone therapy, particularly early after initiation. Absolute risk remains low in most populations but warrants attention in predisposed patients.

Open deep analysis →

Do aromatase inhibitors in men increase bone loss risk?

Aromatase inhibitors lower estradiol and can reduce bone mineral density in men. Routine use to suppress estradiol during testosterone therapy is not supported by outcome evidence and may carry skeletal risk.

Open deep analysis →

Do transdermal and injectable testosterone differ in safety or efficacy?

All FDA-approved formulations can restore testosterone when dosed appropriately. Transdermal routes may have less erythrocytosis than injectable esters in some comparisons, but transfer, adherence, and peak-trough patterns differ by formulation.

Open deep analysis →

Does testosterone therapy worsen obstructive sleep apnea?

Testosterone may worsen sleep apnea in predisposed men. Screening and monitoring for OSA is recommended before and during therapy, especially when symptoms emerge or hematocrit rises.

Open deep analysis →

Does estradiol level affect symptoms and bone health in men on testosterone therapy?

Estradiol in men derives largely from aromatization of testosterone and contributes to bone density and possibly symptom control. Over-suppression with aromatase inhibitors may impair bone health; optimal targets in clinical practice remain debated.

Open deep analysis →

Does testosterone therapy improve depression or low mood in hypogonadal men?

Some randomized trials and meta-analyses show modest improvements in depressive symptoms among men with low testosterone, but effects are heterogeneous and not a substitute for standard psychiatric evaluation when major depression is present.

Open deep analysis →

The Journal of urology · 2026

Testosterone Does Not Drive Prostate Cancer: Presenting the New Framework of Androgen Adequacy vs Inadequacy.

View study →

Cureus · 2026

Psychiatric and Cognitive Effects of Testosterone Therapy in Adult Men: A Systematic Review of Clinical Evidence and Mechanistic Insights.

View study →

Asian journal of andrology · 2025

Clinician's guide to the management of azoospermia induced by exogenous testosterone or anabolic-androgenic steroids.

View study →